Table 6.

Effect of CaP supplementation on faecal excretion of neutral sterols.

Parameter	Placebo	CaP	Change
Coprostanol	430 ± 265	443 ± 259	160 ± 152
(mg/day)	(365–496)	(379–506)	(−47–71)
Cholesterol	160 ± 153	166 ±187	6 ± 121
(mg/day)	(123–198)	(120–212)	(−24–36)
Cholestanol	14 ± 8	13 ± 9	−0.5 ± 5
(mg/day)	(12–16)	(11–16)	(−1.6–0.7)
Coprostanone	41 ± 43	40 ± 33	−1.0 ± 34
(mg/day)	(30–51)	(32–48)	(−9.3–7.3)
Cholestanone	3 ± 3	3 ± 2	0.1 ± 2
(mg/day)	(2–4)	(3–4)	(−0.4–0.6)
Cholestenone	5 ± 4	5 ± 4	0 ± 3
(mg/day)	(4–6)	(4–6)	(−0.8–0.9)

n (studies) = 3; n (subjects) = 66; mean ± standard deviation; (95% confidence interval); CaP: three–four weeks´ intervention with Ca₅(PO₄)₃OH (pentacalcium hydroxy-trisphosphate).